Safety and Persistence of Gene-Modified T Cells for HIV Therapy
Author Information
Author(s): Chono Hideto, Saito Naoki, Tsuda Hiroshi, Shibata Hiroaki, Ageyama Naohide, Terao Keiji, Yasutomi Yasuhiro, Mineno Junichi, Kato Ikunoshin
Primary Institution: Center for Cell and Gene Therapy, Takara Bio Inc, Otsu, Shiga, Japan
Hypothesis
Can MazF-transduced CD4+ T cells be safely infused and persist in cynomolgus macaques?
Conclusion
MazF-transduced CD4+ T cells showed long-term persistence and safety in a non-human primate model, suggesting their potential for HIV gene therapy.
Supporting Evidence
- MazF-transduced CD4+ T cells were detected in the peripheral blood for over six months.
- No significant adverse events were observed in the monkeys after infusion.
- Histopathological analyses showed no lesions related to the infused cells.
- Infused cells suppressed the replication of SHIV 89.6P.
Takeaway
Scientists tested a new treatment for HIV using modified immune cells from monkeys, and found that these cells can stay in the body for a long time without causing harm.
Methodology
The study involved infusing MazF-transduced CD4+ T cells into cynomolgus macaques and monitoring their persistence and safety over six months.
Limitations
The study was conducted in a small sample size of cynomolgus macaques, which may limit the generalizability of the findings to humans.
Participant Demographics
Cynomolgus macaques (Macaca fascicularis), aged 6-7 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website